Greg Madison of Shield: 2022 was landmark year for Accrufer® & Viatris agreement sets us up for a strong 2023
Episode 1184, Feb 14, 2023, 07:55 AM
Greg Madison, CEO of Shield Therapeutics discusses how 2022 was a landmark year for Accrufer® and their Viatris collaborative sales agreement in December has set the company up for a strong growth in 2023.